Challenges of glucose control in ckd
-
Upload
drk-sampath-kumar -
Category
Health & Medicine
-
view
182 -
download
2
description
Transcript of Challenges of glucose control in ckd
![Page 1: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/1.jpg)
Diabetes and KidneyDiabetes and Kidney
Dr.SampathkumarMD,DNB,DM,FRCP
MMHRC
1
![Page 2: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/2.jpg)
2 sides of the coin 2 sides of the coin
2
![Page 3: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/3.jpg)
ALL patients with Diabetes and ALL patients with Diabetes and Proteinuria/Renal failure have Proteinuria/Renal failure have
diabetic renal disease .diabetic renal disease .You may be wrong 50% of the
times !
3
Common Pitfall
![Page 4: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/4.jpg)
Indications for Renal Biopsy Indications for Renal Biopsy
4
![Page 5: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/5.jpg)
Diabetic N along with Infection Diabetic N along with Infection related GN related GN
![Page 6: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/6.jpg)
Endocap. Prolif to 100% crescentsEndocap. Prolif to 100% crescents
![Page 7: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/7.jpg)
Progressive grades of CKDProgressive grades of CKD
7
![Page 8: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/8.jpg)
Filtration Pressure +15 mm Hg Filtration Pressure +15 mm Hg
8
![Page 9: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/9.jpg)
Diabetic glomerular diseaseDiabetic glomerular diseaseFlitration Pressure +35Flitration Pressure +35
9
80 mm
![Page 10: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/10.jpg)
Renal and cv risk increases once Renal and cv risk increases once microalbuminuria crosses 6 mg/gmicroalbuminuria crosses 6 mg/g
Albuminuria Renal risk CV event
0-10 1 1
10-20 2.34 1.9
20-30 12.4 9.8
10
![Page 11: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/11.jpg)
New classification of albumin New classification of albumin excretionexcretion
11
![Page 12: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/12.jpg)
12
![Page 13: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/13.jpg)
13
![Page 14: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/14.jpg)
Traditional Vs Novel Traditional Vs Novel
14
![Page 15: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/15.jpg)
Non Proteinuric nephropathyNon Proteinuric nephropathy
15
![Page 16: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/16.jpg)
16
CKD
![Page 17: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/17.jpg)
17
This patient develops KWD within 5 years though his Hb A1 c was 6.5 %
![Page 18: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/18.jpg)
Insulin dynamics in CKDInsulin dynamics in CKD
18
![Page 19: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/19.jpg)
19
![Page 20: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/20.jpg)
20
![Page 21: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/21.jpg)
Insulin half life in CKDInsulin half life in CKD
21
![Page 22: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/22.jpg)
![Page 23: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/23.jpg)
23
![Page 24: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/24.jpg)
24
![Page 25: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/25.jpg)
Use of OHAs in CKDUse of OHAs in CKD
25
![Page 26: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/26.jpg)
Metformin Controversy Metformin Controversy in CKD….in CKD….
26
![Page 27: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/27.jpg)
Pharmacokinetics of MetforminPharmacokinetics of Metformin
27
![Page 28: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/28.jpg)
MALA- Metformin Associated MALA- Metformin Associated Lactic Acidosis Lactic Acidosis • Decreased Utilisation vs hepatic dysfn
ANAEROBIC GLYCOLYSIS
SHOCK STATES
LIVER DYSFNTYPE B
METFORMIN
•2-10 per 100,000 patients receiving metformin /year•MALA accounts for 0.1-1% total patients admitted to ICU•Mortality is high – 30-50%
Balance
![Page 29: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/29.jpg)
2 sites where Metformin acts2 sites where Metformin acts
29
![Page 30: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/30.jpg)
Hypotension rather than Hypotension rather than metformin level which metformin level which determined Lactate accumulationdetermined Lactate accumulation
30
Conclusion from this study
![Page 31: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/31.jpg)
31
![Page 32: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/32.jpg)
SFU in CKDSFU in CKD
• Depends on Renal or Hepatic metabolism
• Depends also on whether metabolites have hypoglycemic effects
32
![Page 33: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/33.jpg)
33
![Page 34: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/34.jpg)
34
![Page 35: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/35.jpg)
35
![Page 36: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/36.jpg)
36
![Page 37: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/37.jpg)
37
![Page 38: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/38.jpg)
Drug exposure(AUC) in renal impairment compared to patients Drug exposure(AUC) in renal impairment compared to patients with normal renal functionwith normal renal function
Drug Mild RI Moderate RI Severe RI Hemodialysis
Metformin NA NA NA NA
GlibenclamideM1+M2
NA NA -45% NA
GlimepirideM2
NA -55%+100%
-55%+400%
NA
Repaglinide NA +19% +32% +32%
Pioglitazone NA -17% to -43% 17% to -43% NA
Sitagliptin +61% +126% +277% +350%
Vildagliptin +40% +71% +100% NA
Saxagliptin(Active metabolite)
+16%+67%
+41%+192%
+108%+347%
NANA
Alogliptin +70% +110% +220% +280%
Linagliptin +29% +56% +41% +54%
Exenatide -19% -3% NA +227%
A.J Scheen. Expert Opinion on Drug Metabolism and Toxicology: 2013
![Page 39: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/39.jpg)
Linagliptin in a recent study lowered albuminuria on top of Linagliptin in a recent study lowered albuminuria on top of standard ACEi/ARB therapy in patients with T2DMstandard ACEi/ARB therapy in patients with T2DM
39
Linagliptin significantly lowers albuminuria on top of recommended standard treatment for diabetic nephropathy
1. Inclusion criteria: Stable ACE/ARB background; albuminuria 30−3000 mg/g creatinine; GFR > 30.*Albuminuria-lowering evidence for linagliptin will emerge from MARLINA 1218.89.
**ADA 2012, 953-P
Adjusted mean change in albuminuria(24 weeks)1
24 weeks’ treatmentEffect of linagliptin on albuminuria in humans*
n
95% CI
59
-20%, +23%
168
-42%, -22%
Placebo Linagliptin
-4%
-33%
-29%p < 0.05
Albuminuria:
Early marker for renal damage
Marker for endothelial dysfunction
Cardiovascular risk factor
Lowering of albuminuria is associated with kidney & CV protection
Definitions
Microalbuminuria
UACR ≥ 30 mg/g creatinine < 300 mg/g creatinine
Macroalbuminuria
UACR ≥ 300 mg/g creatinine
-29% in albuminuria vs placeboafter 24 weeks’ treatment**
Proven renal safety with potential for additional kidney benefit– Mean GFR remains unchanged after treatment initiation with linagliptin up
to 24 weeks
-29% in albuminuria vs placeboafter 24 weeks’ treatment**
Albuminuria Lowering by Linagliptin is independent of the Improvement in Glucose
Linagliptin significantly lowers albuminuria on top of recommended standard treatment for diabetic nephropathy
1. Inclusion criteria: Stable ACE/ARB background; albuminuria 30−3000 mg/g creatinine; GFR > 30.*Albuminuria-lowering evidence for linagliptin will emerge from MARLINA 1218.89.
**ADA 2012, 953-P
Adjusted mean change in albuminuria(24 weeks)1
24 weeks’ treatmentEffect of linagliptin on albuminuria in humans*
n
95% CI
59
-20%, +23%
168
-42%, -22%
Placebo Linagliptin
-4%
-33%
-29%p < 0.05
Albuminuria:
Early marker for renal damage
Marker for endothelial dysfunction
Cardiovascular risk factor
Lowering of albuminuria is associated with kidney & CV protection
Definitions
Microalbuminuria
UACR ≥ 30 mg/g creatinine < 300 mg/g creatinine
Macroalbuminuria
UACR ≥ 300 mg/g creatinine
-29% in albuminuria vs placeboafter 24 weeks’ treatment**
Proven renal safety with potential for additional kidney benefit– Mean GFR remains unchanged after treatment initiation with linagliptin up
to 24 weeks
-29% in albuminuria vs placeboafter 24 weeks’ treatment**
Possible mechanism: The reno-
protective effect of linagliptin as
studies in preclinical modelInhibition of podocyte damage and
Inhibition of myofibroblast
transformation
Increased GLP-1 receptor
expression
![Page 40: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/40.jpg)
40
![Page 41: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/41.jpg)
41
![Page 42: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/42.jpg)
Extreme Hyperglycemia in CKDExtreme Hyperglycemia in CKD
42
![Page 43: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/43.jpg)
Case HistoryCase History
• 67 yrs old male in altered sensorium• Type 2 Diabetes, CAD • On OHA for the past 5 y• Fever,Dysuria – 7 d• Pain abdoment -1 d• Altered sensorium – 12 h• On Glimepride, Metformin ,Metoprolol,
Losartan, eplerenone,Asprin,atorvastatin
![Page 44: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/44.jpg)
Phy ExaminationPhy Examination
• Significant volume depletion• FEBRILE -101,RR 19 /PM• BP -100/70• JVP-Collapsed• S1,S2 FAINT, Lung Bases - clear• Abdomen- Left Lumbar area tender • Catheter draining turbid urine• Drowsy, Neck supple,No FND,Plantar –
Flexor Bil
![Page 45: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/45.jpg)
LabLab
• Urine – Pus cells +++, Bacteria ++• Hb – 9.8, TC – 18,300. P 84,L14,E2• B.Sugar- 604, B Urea – 87,S.Creat-2.3• Na -147,K – 6.2,Cl – 112, HCO3 – 18.PCO2- 35,pO2 -90• Ketone body – neg• ABG - P H – 7.32
Pyuria Hyperglycemia Azotemia HyperNa,HyperK,Met.Acidosis
![Page 46: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/46.jpg)
3 major grades of insulin deficits 3 major grades of insulin deficits
![Page 47: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/47.jpg)
WHY IS HE NOT WHY IS HE NOT KETONEMICKETONEMIC
![Page 48: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/48.jpg)
Calculated osm
![Page 49: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/49.jpg)
ECF hyperosmolality produces ICF ECF hyperosmolality produces ICF dehydrationdehydration
RF PREVENTS GLYCOSURIA
![Page 50: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/50.jpg)
ICF ECF
Na , GK, P
Urea Water
Ethanol
Insulin lack and hyperosmolality drives K outside
![Page 51: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/51.jpg)
60 kg / 10% Deficit/Na 147 60 kg / 10% Deficit/Na 147
6 / 3L
1 L/I hr
0.45%Sal.
H2O /po
![Page 52: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/52.jpg)
Insulin therapy Insulin therapy
![Page 53: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/53.jpg)
53
![Page 54: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/54.jpg)
![Page 55: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/55.jpg)
Hemodialysis for severe Hemodialysis for severe hyperglycemia in CKDhyperglycemia in CKD
55
Extreme hyperglycemia with ketoacidosis and hyperkalemia in a patient on chronic hemodialysis.Hemodial Int. 2008 Oct ;12 Suppl 2:S43-7.
![Page 56: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/56.jpg)
56
![Page 57: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/57.jpg)
CAPD patientCAPD patient
• Dialysate contains • Glucose in high• Concentration
• Hyperglycemia severe and common
57
![Page 58: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/58.jpg)
Icodextrin use in diabetic patientIcodextrin use in diabetic patient• Icodextrin is
Polymer of Glucose• False high reading of
Blood Glucose if • GDH/PQQ strips
are used • Risk of iatrogenic
hypoglycemia due to misdiagnosis and over reaction
58
![Page 59: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/59.jpg)
Renal Transplantation.Renal Transplantation.
59
![Page 60: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/60.jpg)
Post transplant DiabetesPost transplant Diabetes
• Tacrolimus• Cyclosporine• Steroids• CMV• HCV • Metabolic syndrome
60
![Page 61: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/61.jpg)
45 yrs female , Renal TX in 45 yrs female , Renal TX in MMHRC at 1999.Presents with MMHRC at 1999.Presents with proteinuria , edemaproteinuria , edema
61
![Page 62: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/62.jpg)
Arteriolar hyalinosisArteriolar hyalinosis
62
![Page 63: Challenges of glucose control in ckd](https://reader033.fdocuments.us/reader033/viewer/2022060202/559bf3121a28abff5a8b457e/html5/thumbnails/63.jpg)
63
Hypoglycemia Vs Hyperglycemia in Hypoglycemia Vs Hyperglycemia in CKD- Tight rope walk!CKD- Tight rope walk!
If he falls your reputation also falls !!